[Pembrolizumab (NSCLC, neoadjuvant + adjuvant) – addendum to Project A24-46]

Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018013733
German
Original Title: Pembrolizumab (NSCLC, neoadjuvant + adjuvant) - Addendum zum Projekt A24-46 (Dossierbewertung)
Details
Project Status: Completed
Year Published: 2024
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms
  • Antibodies, Monoclonal, Humanized
  • Immune Checkpoint Inhibitors
Keywords
  • Pembrolizumab
  • Carcinoma – Non-Small-Cell Lung
  • Benefit Assessment
  • NCT03425643
Contact
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Siegburger Str. 237, 50679 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.